(OAKVILLE, Ontario) February 22, 2022 ­– FORUS Therapeutics, a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer, today announced it has secured $2.5M CAD in growth capital...

FORUS Therapeutics is delighted to introduce Marie-Josèphe Champagne as the Senior Medical Science Liaison for Québec and Atlantic Canada.  Marie-Josèphe has over 18 years of experience in the pharmaceutical industry in commercial and medical affairs roles, primarily...

Despite all the global and local challenges; related and unrelated to the pandemic, 2021 has been a year of tremendous growth, progress and development at FORUS. We are excited about 2022 and look forward to fulfilling our mission by bringing innovative new medicines...